コロ・バイオ
Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.07 | $0 | -$17M |
| 2026 Q1 | -1.69 | $0 | -$16M |
| 2025 Q4 | -5.33 | $1M | -$18M |
| 2025 Q3 | -1.92 | $1M | -$17M |
| 2025 Q2 | -2.74 | $1M | -$19M |
| 2025 Q1 | -2.49 | $3M | -$25M |
| 2024 Q4 |
| -2.26 |
| $2M |
| -$9M |
| 2024 Q3 | -2.26 | $0 | -$21M |